- Pop Mart reported H1 2026 revenue of CNY 17.17 billion, marking a 23.8% year-over-year increase.
- Adjusted net profit climbed 23.8% to CNY 5.16 billion, alongside a gross margin of 69.7%.
- Plush category revenue surged 60% to CNY 9.82 billion, while the store network expanded to 676 stores and 2,827 roboshops.
- POP MART announced plans to launch a share buyback program ranging from RMB 2 billion to RMB 5 billion within the next 6 months.
- CEO Wang Ning stated that the company faces significant performance pressure due to last year's high base, making the full-year revenue growth target of 20% unlikely to be achieved.
- Wang noted that 2026 is positioned as a year for operational adjustment rather than prioritizing sales growth.
- POP MART announced its interim results for the period ended June 2026, reporting revenue of RMB 17.173 billion and a net profit of RMB 5.038 billion.
- Revenue increased by 23.8% year-on-year, while net profit grew by 10.1% year-on-year, both missing market expectations.
- The company recorded an EPS of RMB 3.8 with no dividend declared for the period.
- Pop Mart is projected to report a sharp slowdown in first-half revenue growth to 44 per cent, down from over 200 per cent a year earlier, alongside a significant drop in its market value.
- The company faces mounting short-seller pressure and weakening domestic online demand as trend-driven consumers shift focus away from viral novelty items.
- To sustain long-term growth and transition into a broader entertainment franchise, Pop Mart is expanding its physical theme parks, pursuing international outlets, and developing character movies.
- The 2026 market reality check demonstrates that various Hong Kong-listed companies can no longer rely on past achievements to sustain their valuations.
- Major telecom operators face traditional business declines despite expanding into computing power, while Pop Mart confronts slowing overseas sales and a lowered growth outlook.
- Meanwhile, WuXi Biologics successfully divested non-core assets to focus on antibody-drug conjugate capacity, whereas other firms struggle with legacy issues or margin pressures.